Core Laboratories Inc 2024年度报告

☐ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR For the transition period from ________________ to _______________ Commission File Number 001-41695 CORE LABORATORIES INC. (Exact name of registrant as specified in its charter) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☐ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☐No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).Yes☐No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reportingcompany, or emerging growth company. See definition of "large accelerated filer," "accelerated filer" and "smaller reporting company" and"emerging growth company" in Rule 12b-2 of the Exchange Act.Large accelerated filer☐Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of itsinternal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered publicaccounting firm that prepared or issued its audit report.☐If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ As of June 30, 2024, the aggregate market value of common stock held by non-affiliates of the registrant was approximately $938,376,082. As of January 31, 2025, the number of shares of common stock of the registrant outstanding was 46,826,820. DOCUMENTS INCORPORATED BY REFERENCE The information required by Part III of this Report, to the extent not set forth herein, is incorporated herein by reference from the registrant’sdefinitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2025, which definitive proxy statement shall be filedwith the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report relates. CORE LABORATORIES INC.FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024TABLE OF CONTENTS Page PART IItem 1.Business1Item1A.Risk Factors10Item1B.Unresolved Staff Comments20Item1C.Cybersecurity20Item 2.Properties21Item 3.Legal Proceedings22Item 4.Mine Safety Disclosures22PART IIItem 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities23Item 6.[Reserved]24Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations25Item7A.Quantitative and Qualitative Disclosures about Market Risk38Item 8.Financial Statements and Supplementary Data39Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure39Item9A.Controls and Procedures39Item9B.Other Information40Item9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections40PART IIIItem 10.Directors, Executive Officers and Corporate Governance41Item 11.Executive Compensation41Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters41Item 13.Certain Relationships and Related Transactions and Director Independence41Item 14.Principal Accountant Fees and Services41PART IVItem 15.Exhibit and Financial Statement Schedules42Item 16.Form 10-K Summary42 PART I ITEM 1. BUSINESS General Core Laboratories Inc. is a Delaware corporation. We were established in 1936 and are one of the world’s leadingproviders of proprietary and patented reservoir description and production enhancement services and products tothe oil and gas industry, primarily through client relationships with many of the world’s major, nat